Fever and neutropenia in cancer patients: the diagnostic role of cytokines in risk assessment strategies

CSMO Nijhuis, SMGJ Daenen, E Vellenga, WTA van der Graaf, JA Gietema, HJM Groen, WA Kamps, ESJM de Bont*

*Bijbehorende auteur voor dit werk

Onderzoeksoutputpeer review

27 Citaten (Scopus)


Cancer patients treated with chemotherapy are susceptible to bacterial infections. Therefore, all neutropenic cancer patients with fever receive standard therapy consisting of broad-spectrum antibiotics and hospitalization. However, febrile neutropenia in cancer patients is often due to other causes than bacterial infections. Therefore, standard therapy should be re-evaluated and new treatment strategies for patients with variable risk for bacterial infection should be considered. This paper reviews the changing spectrum of microorganisms and resistance of microorganisms to antibiotics in infection during neutropenia and discusses new strategies for the selection of patients with low-risk for bacterial infection using clinical and biochemical parameters such as acute phase proteins and cytokines. These low-risk patients may be treated with alternative therapies such as oral antibiotics, early discharge from the hospital or outpatient treatment. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.

Originele taal-2English
ArtikelnummerPII S1040-8428(01)00220-7
Pagina's (van-tot)163-174
Aantal pagina's12
TijdschriftCritical Reviews in Oncology/Hematology
Nummer van het tijdschrift2
StatusPublished - nov.-2002

Citeer dit